Login to Your Account



Other News To Note


Thursday, August 1, 2013
• Elusys Therapeutics Inc., of Pine Brook, N.J., released data from three completed studies of ETI-204 (Anthim), an anthrax anti-toxin, administered by intramuscular injection (IM). Two of the studies assessed IM administration of ETI-204 following challenge with aerosolized B. anthracis spores (either before or after the development of symptoms of anthrax).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription